BD To Shift China-Facing Production, Ramp Up US Output With $2.5B To Counter Tariff Blow

FY25 Tariff Hit Largely Tied To Q4, But Analysts See $1EPS Risk Next Year.

For FY25, BD expects a $90m pretax tariff expense – approximately $0.25 in adjusted diluted EPS impact – mostly affecting the fourth quarter.

More from Strategy

More from Medtech Insight